Article Text
Abstract
Decision theorists recognise that information is valuable only insofar as it has the potential to change a decision. This means that since acquiring more information is time-consuming and sometimes expensive, judgements need to be made about what information is most valuable to acquire, and whether it is worth acquiring at all. In this article I apply this idea to informed consent and argue that the most valuable information relates not to what the best treatment option may be but to possible futures a patient may regret. I conclude by proposing a regret-minimisation framework for informed consent that I contend better captures the true nature of shared decision making than existing formulations.
- Informed Consent
- Ethics
- Quality of Health Care
Statistics from Altmetric.com
Footnotes
Twitter @NarcyzGhinea
Contributors NG conceived, conceptualised and wrote this article.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Read the full text or download the PDF:
Other content recommended for you
- Choosing wisely in oncology: necessity and obstacles
- ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016
- Report on the status of women occupying leadership roles in oncology
- The hard road to ranking the clinical benefit of antineoplastic agents: ESMO Award 2016 presentation
- ESMO gave me a chance to help make a difference: a personal reflection on the occasion of receiving the 2015 ESMO Award
- Severity of COVID-19 in patients with lung cancer: evidence and challenges
- Global cancer control: responding to the growing burden, rising costs and inequalities in access
- First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study
- One year of ESMO Open: Cancer Horizons—where are we going from here?
- Back to the ‘essence’ of medical treatment in oncology: the 2015 WHO Model List of Essential Medicines